SolasCure

Revolutionising wound care with biomimicry and evidence-based medicine

[SolasCure @SolasCure]

Aurase Wound Gel has demonstrated an excellent safety and tolerability profile: no underlying treatment-related safety or local tolerability issues at 24 U/mL, no need for anesthesia or analgesia, and no additional pain vs standard of care.

#PatientReportedOutcome

[SolasCure @SolasCure]

In chronic wound drug development, hard data separates an “interesting signal” from a de-risked mechanism.

In SolasCure’s latest Phase 2 study, Aurase Wound Gel showed a strong correlation between 4-week slough reduction & wound area reduction (r=0.7552, p=0.0072).

#WoundCare

[SolasCure @SolasCure]

In its latest Phase II clinical trial, Aurase Wound Gel has delivered consistent, highly significant improvements in both debridement and healing versus control.

#ClinicalData #Phase2 #AuraseWoundGel #SolasCure #Efficacy #WoundHealing #Debridement

[SolasCure @SolasCure]

Aurase Wound Gel has demonstrated an excellent safety and tolerability profile: no underlying treatment-related safety or local tolerability issues at 24 U/mL, no need for anesthesia or analgesia, and no additional pain vs standard care.

#SafetyProfile #AuraseWoundGel

[SolasCure @SolasCure]

Aurase Wound Gel works through two simultaneous mechanisms of action: continuous enzymatic debridement and active PAR2-mediated healing.

The result is a continuously clean, physiologically optimal wound bed that is actively stimulated to heal, rather than passively maintained.

[SolasCure @SolasCure]

Aurase Wound Gel (AWG) is SolasCure’s Phase 2 biologic designed to be the first-line therapy for both debridement and healing across chronic wounds.

For investors, that is not just a better product — it is a mechanistic paradigm shift in wound care.

#AuraseWoundGel #Biotech

[SolasCure @SolasCure]

Aurase Wound Gel (AWG) is SolasCure’s Phase 2 biologic designed to be the first-line therapy for both debridement and healing across chronic wounds.

For investors, that is not just a better product — it is a mechanistic paradigm shift in wound care.

#BiologicTherapy #Biotech

[SolasCure @SolasCure]

SANTYL, the current enzymatic incumbent, debrides slowly and has limited impact on time to closure.

The market is telling a clear story: better debridement is not enough — the next generation must debride and heal.

#Debridement #WoundHealing #StandardOfCare #BiotechInnovation

[SolasCure @SolasCure]

Around ~5 million Americans live with chronic, non-healing wounds, costing the healthcare system over $25 billion every year.

SolasCure was founded to change that equation with a dual-action biologic that both debrides and heals wounds.

#ChronicWounds #WoundCare

[SolasCure @SolasCure]

NEWS: SolasCure is delighted to announce that it has been selected to receive the European Innovation Council’s @EUeic Accelerator Grant to continue development of its innovative wound care technology.

Read more: https://t.co/0LXgf3Cz5S

#woundcare #chronicwounds #EIC

[SolasCure @SolasCure]

SolasCure welcome Lee Harle as our Chief Business Officer, responsible for spearheading our market-entry strategy.

Lee brings 25+ years’ experience building successful businesses & joint-ventures in consumer goods, technology & life-science industries worldwide.

[SolasCure @SolasCure]

SolasCure announces £10.9m Series B fundraise to advance #woundcare innovation.
The funding supports development of Aurase Wound Gel, progressing clinical trials of this innovative wound debriding enzyme following completion of the Phase IIa safety study: https://t.co/RylVsw9H6W

[SolasCure @SolasCure]

SolasCure are delighted to be named a top Biopharma companies in Cambridgeshire.

SolasCure’s pioneering aim to develop efficacious wound care products by leveraging maggot enzyme earned a place, alongside the likes of Astra Zeneca & Healx.

#woundcare

https://t.co/3q5o9MfZ7P

[SolasCure @SolasCure]

SolasCure are delighted to have been selected as a UK Life Sciences Innovator 2023. This is significant recognition by @tradegovukMEAP of our propriety technology as we work to develop revolutionary wound care treatments.

#LSI2023 #UKInnovation #LifeSciences #Future #Technology

[SolasCure @SolasCure]

SolasCure is delighted to announce that CTO Dr Bela Kelety will be speaking at this year’s Pharma Contract Manufacturing conference in Berlin from 28th -30th March, sharing insights on the importance of scaling up for start-ups.

@PharmaIQ
#pharmaevents #PCM2023 #biotech

[SolasCure @SolasCure]

We are delighted that David Fairlamb, Director of Regulatory Affairs at SolasCure, has won the Futures category at the TOPRA awards, which recognises the role of regulatory scientists in realising the potential of cutting-edge technologies.

Learn more: https://t.co/nbgmmM5DMm

[SolasCure @SolasCure]

SolasCure's toxicology & pre-clinical research programme has been published in the International Wound Journal, with the enzyme used in Aurase Wound Gel shown to have a good safety profile.

Read more: https://t.co/qpRNKdW5TS

#woundcare #IWJ #chronicwounds

[SolasCure @SolasCure]

Meet Oliver Schofield, Chief Financial Officer at SolasCure. Oliver is an experienced biotech start-up CFO & previously worked in management consulting at KPMG. He is also CIMA certified.
Read more about wound care problems SolasCure is looking to solve: https://t.co/6dEvEbLi9G

[SolasCure @SolasCure]

We're delighted to announce that David Fairlamb, Director of Regulatory Affairs at SolasCure, has won the Futures category at the TOPRA awards, recognising the role of regulatory scientists in realising the potential of cutting-edge technologies.

Read on: https://t.co/jysoOzAsdr

[SolasCure @SolasCure]

Meet David Fairlamb, Director of Regulatory Affairs at SolasCure. David has over 30 years of global Regulatory Affairs experience working in industry & consultancy within drug, biologics, medical devices & combination products https://t.co/6dEvEbtGL6